Improvement of Personalized Cancer Care for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Through Digital Connection of Specialized Cancer Centers, Community Hospitals, Private Practices and Patients (DigiNet)

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care. The DigiNet project is based on the established precision medicine program, the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, whereby every patient receives molecular diagnostics and personalized therapy information after the initial diagnosis. Within the framework of the DigiNet project, specialized academic centers will be digitally connected with practitioners via a shared project database. Furthermore, a committee of experts will monitor the course of treatment and will advise the practitioners in case of critical conditions. Additionally, patient-reported outcomes will be incorporated into the treatment.

Start Date01 Jun 2022

Sponsor / Collaborator

Barmer

[+8]

NCT05934032

/ RecruitingNot ApplicableIIT

Registry of the National Network Genomic Medicine Lung Cancer (nNGM), Linking Data on Molecular Diagnostics, Clinical Characteristics, Treatment Patterns and Outcomes of Subjects With Non-Small Cell Lung Cancer in Germany

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400 general hospitals and oncological practices in Germany

Start Date01 Apr 2018

Sponsor / Collaborator

Universitätsklinikum Schleswig-Holstein

[+16]

100 Clinical Results associated with HELIOS Klinikum Emil von Behring GmbH

0 Patents (Medical) associated with HELIOS Klinikum Emil von Behring GmbH

461

Literatures (Medical) associated with HELIOS Klinikum Emil von Behring GmbH

31 Dec 2025·COPD: Journal of Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Lung Volume Reduction with Endobronchial Coil #2 and Coil #4 Results of the German Emphysema Registry—Lungenemphysemregister e.V.

Article

Author: Grah, Christian ; Oei, Shiao Li ; Barten-Neiner, Grit ; Hübner, Ralf-Harto ; Blazejczyk, Katarzyna ; Fertl, Andreas ; Becke, Birgit ; Eisenmann, Stephan ; Wüstefeld, Hannah ; Schmidt, Bernd ; Sgarbossa, Thomas ; Geltner, Christian ; Franke, Karl-Josef ; Stanzel, Franz ; Wiesemann, Björn ; Krist, Joanna ; Schwick, Björn

BACKGROUNDClinical trials have shown beneficial results from lung volume reduction with endobronchial coils in patients with emphysema, but comprehensive safety data are not yet available for a new coil type, Coil #4. The objective of this study is to generate real-world data (RWD) on the safety and efficacy of endobronchial Coil #2 and Coil #4.METHODSThis is a cohort study of prospectively collected data from the multicenter German Lung Emphysema Registry e.V. (LE-Registry) for patients with advanced lung emphysema undergoing lung volume reduction. All patients treated with Coil #2 or Coil #4 were evaluated at baseline and at 3 months for pulmonary function tests (FEV₁, FVC, RV, DLCO, pCO₂), exercise capacity, quality of life (mMRC, CAT, SGRQ), and adverse events. Descriptive statistics were used to analyze response rates and changes in clinical outcomes.RESULTSData from 73 patients (37 Coil #2, 36 Coil #4) enrolled between 2017 and 2024 were evaluated. At 3 months, outcome data were available for 32 Coil #2 and 26 Coil #4 patients. In the Coil #2 cohort significant improvements in RV and SGRQ were observed. The Coil #4 cohort shows significant improvements in FVC, RV, SGRQ, and CAT. Complications occurred in 37% of Coil #2 and 37% of Coil #4 patients, with 26% of patients treated with Coil #4 experiencing pneumothorax.CONCLUSIONSThe outcomes observed in this RWD study are consistent with other published coil studies. The higher pneumothorax rate with Coil #4 is surprising and should be minimized by adapting the technique.TRIAL REGISTRATIONDRKS00021207 registered on 29/05/2020.

01 Jul 2025·The American Journal of Cardiology

Fasting Versus Nonfasting Before Cardiac Catheterization—Are We Asking the Right Questions?

Letter

Author: Nickel, Eike A ; Rüggeberg, Anne

01 May 2025·European Journal of Cancer

AI integrations with lung cancer screening: Considerations in developing AI in a public health setting

Review

Author: Naghavi, Morteza ; Yip, Rowena ; Yang, Pan-Chyr ; Reeves, Anthony P ; Pastorino, Ugo ; Flores, Raja ; Taoli, Emanuela ; Aldige, Carolyn ; Grannis, Frederic W ; Field, John ; Silva, Mario ; Smith, Robert ; Rizzo, Albert ; Blum, Torsten ; Oudkerk, Matthijs ; Henschke, Claudia I ; Wu, Ning ; Yankelelvitz, David F ; Kelly, Karen ; Seijo, Luis M ; Kazerooni, Ella A ; Schneider, Victoria ; Shaham, Dorith ; Ross, Sheila ; Walstra, Anna N H ; Osarogiagbon, Raymond ; Myers, Kyle J ; Viola, Lucia ; Montuenga, Luis M ; Gratama, Jan Willem C ; Fain, Sean B ; Mulshine, James L ; Pyenson, Bruce S ; Avila, Ricardo S ; Healton, Cheryl ; Ten Haaf, Kevin ; Lancaster, Harriet L ; Gipp, Ilya ; de Koning, Harry J ; Cham, Matthew ; Vogel-Claussen, Jens ; van der Aalst, Carlijn M ; Giger, Maryellen L

Lung cancer screening implementation has led to expanded imaging of the chest in older, tobacco-exposed populations. Growing numbers of screening cases are also found to have CT-detectable emphysema or elevated levels of coronary calcium, indicating the presence of coronary artery disease. Early interventions based on these additional findings, especially with coronary calcium, are emerging and follow established protocols. Given the pace of diagnostic innovation and the potential public health impact, it is timely to review issues in developing useful chest CT screening infrastructure as chest CT screening will soon involve millions of participants worldwide. Lung cancer screening succeeds because it detects curable, early primary lung cancer by characterizing and measuring changes in non-calcified, lung nodules in the size-range from 3mm to 15 mm in diameter. Therefore, close attention to imaging methodology is essential to lung screening success and similar image quality issues are required for reliable quantitative characterization of early emphysema and coronary artery disease. Today's emergence of advanced image analysis using artificial intelligence (AI) is disrupting many aspects of medical imaging including chest CT screening. Given these emerging technological and volume trends, a major concern is how to balance the diverse needs of parties committed to building AI tools for precise, reproducible, and economical chest CT screening, while addressing the public health needs of screening participants receiving this service. A new consortium, the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE^DxRx) is committed to facilitate broad, equitable implementation of multi-disciplinary, high quality chest CT screening using advanced computational tools at accessible cost.

100 Deals associated with HELIOS Klinikum Emil von Behring GmbH

100 Translational Medicine associated with HELIOS Klinikum Emil von Behring GmbH

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

HELIOS Klinikum Emil von Behring GmbH

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 12 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing